Semaglutide’s impact on lowering insulin doses in adults with type 1 diabetes and obesity using automated insulin pumps

Duality of Interest. H.K.A. reports receiving research funding from Dexcom, Abbott, Roche, Medtronic, and Tandem and receiving honorarium for consulting from Dexcom, Medtronic, Tandem, Roche. D.K. reports receiving research support from Insulet, Abbott, Tandem Diabetes Care, Sequel Med Tech, and the National Institutes of Health (NIH) and has received personal fees from Dexcom, Insulet, Novo Nordisk, Eli Lilly, Abbott, Corcept Therapeutics, Tandem Diabetes Care, CeQur, Mannkind, Ascentia Diabetes Care, Arcor, Structural Therapeutics, and Sanofi for speaking, consulting, or serving on advisory boards. A.A. reports receiving honoraria from Medtronic for consulting. A.B. has received research funding from Amgen, Endogenix, Gasherbrum Bio, vTv Therapeutics, Boehringer Ingelheim Pharmaceuticals, Abbott Diabetes Care, AbbVie, Covance, Dexcom, Eli Lilly and Company, Madrigal Pharmaceuticals, Medtronic, Novo Nordisk, MannKind Corporation, Carmot Therapeutics, Quintiles, Akero Therapeutics, 89 bio, Viking Therapeutics, Barbara Davis Center for Diabetes, PPD, Zydus Therapeutics, Kowa Pharmaceuticals America, Insulet Corporation, and Verdiva Bio and fees not relevant to the present study for advising, consulting, or speaking from Verdiva Bio, Boehringer Ingelheim Pharmaceuticals, and Novo Nordisk. C.R.L. reports research funding from 89bio, Abbott Diabetes Care, AbbVie, Akero Therapeutics, Amgen, Astra Zeneca, Barbara Davis Center for Diabetes, Boehringer Ingelheim Pharmaceuticals, Carmot Therapeutics, DEKA Research Corporation, Dexcom, Eli Lilly and Company, Endogenix, Gasherbrum Bio, MannKind Corporation, Medtronic, Novo Nordisk, Verdiva Bio Dev Limited, Viking Therapeutics, vTv Therapeutics, Zealand Pharma, and Zydus Therapeutics. V.N.S. reports the institution with which he is affiliated has received research funding from Alexion, Eli Lilly, Enable Bioscience, Zucara Therapeutics, Cystic Fibrosis Foundation, Breakthrough T1D, and the NIH. V.N.S. has received honoraria not related to the present study from Novo Nordisk, Eli Lilly, Sanofi, Embecta, Medtronic, Dexcom, Insulet, Ascensia Diabetes Care, Abbott Diabetes Care, Tandem Diabetes Care, Biomea Fusion, Sequel Med Tech, Roche, and T1D Scout for advising, and/or consulting. C.A.A. and J.R. are employees of Breakthrough T1D. No other potential conflicts of interest relevant to this article were reported.